A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

NCT02034552 | Completed Phase 2 Results

• 1 other identifier: 16544
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 19

Brief Summary

The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA). The safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide will be investigated. The study will evaluate radiological progression free survival, overall survival, and skeletal events. This study will also explore the clinical utility of different imaging modalities (whole body quantified technetium-99 bone scan, DW-MRI \[diffusion-weighted magnetic resonance imaging\] and NaF \[sodium fluoride\] PET-CT \[positron emission tomography-computed tomography\] scan) and will have a separate central radiological review for applicable secondary and exploratory imaging endpoints. All subjects will be randomized as assigned randomly by the IXRS (interactive voice / web response system) system in a 1:1:1 ratio into one of the treatment arms: radium-223 dichloride alone, 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks for up to 6 doses; radium-223 dichloride, 50 kBq/kg (55 kBq/kg after implementation of NIST update) every 4 weeks up to 6 doses together with abiraterone acetate 1,000 mg daily and prednisone 5 mg bid (twice daily); radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) every 4 weeks up to 6 doses together with enzalutamide 160 mg daily. The study will consist of screening, treatment and follow-up periods. Study will continue until disease progression as determined by investigator, or when patient meets criteria for withdrawal from study. Subjects in treatment arms with abiraterone/prednisone or enzalutamide will have the option to continue taking oral study therapy until the end of the study (2 years from the last dose of radium-223 dichloride) if the investigator deems the subject may benefit and there is no clinical or radiological progression. Subjects who discontinue all study treatment prior to 2 years from last radium-223 dichloride treatment will enter active follow-up. During the active follow-up period, the subject will have a safety visit at the clinic every 12 weeks from the EOT (end of treatment) for up to 2 years from the last dose of radium-223 dichloride. Beyond 2 years from last radium-223 dichloride treatment,subjects will enter long-term follow-up and will be followed via phone contact at intervals to assess for safety (hematological toxicity and new primary malignancies) and overall survival. A separate long-term safety follow-up study protocol is planned. Once implemented, the study subjects surviving after the end of the active follow-up will be transitioned to this separate long-term safety follow-up protocol.

Conditions

Prostatic Neoplasms

Outcome Measures

Primary Outcomes (2)

• Patient Bone Scan Response Rate

  Radiological bone scan response based on change from baseline of digitized technetium-99 bone scans using computer-aided detection software. Responder (R): 30% or greater resolution of the BSLA compared to baseline. Stable Disease (SD): Not meeting the criteria for R, PD, or UE. Progressive Disease (PD): Two or more new areas of radiotracer uptake attributable to metastatic disease in regions of bone that had not previously shown radiotracer uptake or greater than 30% increase from baseline in BSLA attributable to metastatic disease. Unable to Evaluate (UE): Assigned if bone scan results cannot be interpreted due to inconsistent image acquisition parameters compared to the reference scan, incomplete imaging, or other similar technical deficiencies.

  At 24 weeks

• Bone Scan Lesion Area

  Bone scan lesion area was defined as the sum of the pixel areas (cm2) of the set of the whole body technetium-99 bone scan imaging pixels identified as bone lesion.

  At 24 weeks

Secondary Outcomes (6)

• Radiological Progression Free Survival

  From randomization to radiological disease progression or death from any cause (about 30.82 months )

• Time to Radiological Progression

  From the randomization date to the date of radiological disease progression (about 30.82months)

• Time to Radiological Bone Progression

  From the randomization date to the date of radiological bone progression (about 30.82 months)

• Time to First Symptomatic Skeletal Event

  From the randomization date to the first SSE on or following the randomization date (about 30.82 months)

• Symptomatic Skeletal Event-free Survival

  From the randomization date to the first SSE on or following the randomization date or death, whichever occurred first (about 32.39 months)

Study Arms (3)

Radium-223 dichloride (Xofigo, BAY88-8223)

EXPERIMENTAL

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Radium-223 with abiraterone&prednisone

EXPERIMENTAL

Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug: Abiraterone acetate; Drug: Prednisone

Radium-223 with enzalutamide

EXPERIMENTAL

Drug: Radium-223 dichloride (Xofigo, BAY88-8223); Drug: Enzalutamide

Interventions

Radium-223 dichloride (Xofigo, BAY88-8223) DRUG

Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus

Radium-223 dichloride (Xofigo, BAY88-8223); Radium-223 with abiraterone&prednisone; Radium-223 with enzalutamide

Abiraterone acetate DRUG

Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride

Radium-223 with abiraterone&prednisone

Prednisone DRUG

Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride

Radium-223 with abiraterone&prednisone

Enzalutamide DRUG

Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride

Radium-223 with enzalutamide

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed adenocarcinoma of the prostate
• Known castration-resistant disease
• Serum PSA ≥2 ng/mL (μg/L)
• Multiple skeletal metastases (≥2 hot spots) on bone scan
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2.
• Life expectancy ≥6 months
• Adequate hematologic, hepatic, and renal function

You may not qualify if:

• History of visceral metastasis, or visceral metastases
• Malignant lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter
• Medical condition that would make prednisone (corticosteroid) use contraindicated
• Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone bid
• Treatment with more than one chemotherapy agent for prostate cancer
• Prior systemic radiotherapy and hemibody external radiotherapy
• History of pituitary or adrenal dysfunction
• Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone)
• Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy
• History of seizures (taking/not taking anticonvulsants), arteriovenous malformation in the brain, head trauma with loss of consciousness
• Central nervous system (CNS) metastases

Sponsors & Collaborators

• Bayer: lead

Study Sites (19)

Unknown Facility

Scottsdale, Arizona, 85251, United States

Location

Unknown Facility

Tucson, Arizona, 85704, United States

Location

Unknown Facility

Los Angeles, California, 90033, United States

Location

Unknown Facility

New Haven, Connecticut, 06520, United States

Location

Unknown Facility

Newark, Delaware, 19713, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20007, United States

Location

Unknown Facility

Plantation, Florida, 33324, United States

Location

Unknown Facility

Indianapolis, Indiana, 46202, United States

Location

Unknown Facility

New Orleans, Louisiana, 70112, United States

Location

Unknown Facility

Shreveport, Louisiana, 71103, United States

Location

Unknown Facility

Rockville, Maryland, 20850, United States

Location

Unknown Facility

Detroit, Michigan, 48201, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Omaha, Nebraska, 68130, United States

Location

Unknown Facility

Syracuse, New York, 13210, United States

Location

Unknown Facility

The Bronx, New York, 10467-2490, United States

Location

Unknown Facility

Springfield, Oregon, 97477, United States

Location

Unknown Facility

Houston, Texas, 77027, United States

Location

Unknown Facility

Seattle, Washington, 98109, United States

Location

Related Publications (1)

• Petrylak DP, Vaishampayan UN, Patel KR, Higano CS, Albany C, Dawson NA, Mehlhaff BA, Quinn DI, Nordquist LT, Wagner VJ, Siegel J, Trandafir L, Sartor O. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open. 2021 Apr;6(2):100082. doi: 10.1016/j.esmoop.2021.100082. Epub 2021 Mar 19.

  PMID: 33744812 DERIVED

Related Links

• Click here to find results for studies related to Bayer products.

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

radium Ra 223 dichloride; Abiraterone Acetate; Prednisone; enzalutamide

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Pregnadienediols; Pregnadienes; Pregnanes

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: Bayer

clinical-trials-contact@bayer.com

(+)1-888-84 22937

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2013
• First Posted: January 13, 2014
• Study Start: March 7, 2014
• Primary Completion: July 15, 2016
• Study Completion: June 26, 2018
• Last Updated: July 23, 2019
• Results First Posted: July 2, 2017

Record last verified: 2019-07

Locations

US (19)